Exact Sciences (EXAS) isn't just a diagnostics company anymore; it’s officially a "will-they-won't-they" drama for Wall Street. If you’re checking the exas stock price today, you’ll see it sitting around $102.43. It’s been a wild ride. The stock closed Friday with a modest gain of 0.09%, which sounds boring until you realize it has been climbing for seven straight days.
People are talking. Specifically, they're talking about Abbott Laboratories.
The $105 Question
Honestly, the biggest thing moving the needle right now isn't even the lab results. It’s a massive rumor—well, more than a rumor. Investigative law firms like Kahn Swick & Foti are currently looking into a proposed sale of Exact Sciences to Abbott Laboratories (NYSE: ABT) for $105.00 per share in cash.
That $105 figure is basically a magnet for the stock price.
🔗 Read more: Is Today a Holiday for the Stock Market? What You Need to Know Before the Opening Bell
Investors are trying to figure out if that price is a fair deal. Some analysts, like those at Jefferies and JPMorgan, have already nudged their targets toward that $105–$118 range. But then you have the skeptics. There are law firms basically shouting from the rooftops that the company might be worth more, especially with the recent launch of Cologuard Plus.
Is it a buy at $102 if the "ceiling" is $105? That’s the tightrope everyone is walking.
Why the Bulls are Obsessed
Exact Sciences has spent years burning through cash to dominate the "poop-in-a-box" market. It worked. Cologuard is a household name now.
💡 You might also like: Olin Corporation Stock Price: What Most People Get Wrong
- Cologuard Plus is a beast. Launched in early 2025, it reduced false positives by 40% compared to the original version. That matters because insurance companies hate paying for unnecessary colonoscopies.
- Revenue is actually soaring. In late 2025, the company reported $851 million in quarterly revenue, a 20% jump.
- The Multi-Cancer Dream. They recently launched Cancerguard, a blood test designed to catch multiple types of cancer early. If this goes mainstream, $105 might actually look cheap in hindsight.
But don't get it twisted—the company still isn't "profitable" in the traditional, boring sense. They lost about $20 million last quarter. For a company valued at nearly **$20 billion**, that makes some value investors break out in hives.
The Technicals: What the Charts Say
Technically, the exas stock price today is flirting with its 52-week high of $102.66. When a stock hits a wall like that, it usually does one of two things: it smashes through or it bounces back down to its 50-day moving average, which is currently sitting way lower at $90.80.
The Relative Strength Index (RSI) is hovering around 40, which is neutral territory. It's not "overbought" yet, but seven days of green candles usually mean a "cooling off" period is coming.
📖 Related: Funny Team Work Images: Why Your Office Slack Channel Is Obsessed With Them
What Most People Get Wrong
Most casual observers think EXAS is a one-trick pony with Cologuard. They're wrong. The Precision Oncology side of the house, which includes the Oncotype DX tests, is quietly pulling in over $180 million a quarter. This is the stuff that helps doctors decide if a breast cancer patient actually needs chemotherapy. It's high-margin, sticky revenue that provides a floor for the stock when people get worried about screening volumes.
Real Talk for Your Portfolio
If you're looking at exas stock price today as a quick flip, you're playing a dangerous game with the Abbott merger news. If the deal falls through, that $105 support disappears, and the stock could easily slide back to the mid-$80s where the analysts' median targets used to live.
On the flip side, if another bidder like Roche or Thermo Fisher enters the chat? Then we’re looking at a bidding war.
Actionable Insights for Investors
- Watch the $105 Level: This is the current "gravity" for the stock. If it breaks above this on high volume, it means the market expects a higher buyout offer.
- Monitor the Legal Noise: Keep an eye on those shareholder "investigations." They rarely stop a deal, but they can force a price adjustment.
- Mind the Gap: The 200-day moving average is all the way down at $61. That is a massive gap. If the merger talk dies, the "air" under this stock is thin.
- Next Earnings Date: Mark February 18, 2026 on your calendar. That’s the next big data dump that will prove if the 2025 growth was a fluke or the new normal.
The smart move right now isn't chasing the 1% gain left before the rumored buyout price. It's deciding if you believe in the long-term "Cancerguard" pipeline enough to hold through the volatility if the Abbott deal hits a regulatory snag.